论文部分内容阅读
观察肝癌患者PBMC在体外诱导成CIK细胞的能力及其对肝癌细胞的细胞毒作用。对比正常人组和肝癌患者组CIK细胞和LAK细胞之间的扩增差异。用流式细胞仪检测CIK细胞表面标志CD3、CD5 6 ,3 H TdR释放法检测CIK细胞、LAK细胞对肝癌细胞系SMMC 772 1等多种细胞系的细胞毒作用。结果显示 ,肝癌组和正常组的CIK细胞扩增倍数分别达 6 4 3倍和6 7 4倍 ,CD3+CD5 6 +细胞扩增倍数均达 6 0 0倍以上 ,在细胞扩增曲线及细胞表面标志上无差异 ,远大于LAK细胞 ;肝癌组CIK对肝癌细胞SMMC 772 1、Bel 74 0 2、Hep 3b杀伤能力均达 6 5 %～ 81% ,与正常组相同 ,且与对肠癌细胞系HIC 2 5 1杀伤能力无差异 ;对正常胎肝细胞系L 0 2的细胞毒作用 <5 % ;肝癌患者CIK对耐药的和未诱导耐药的K5 6 2细胞细胞毒作用均达到 70 %左右。肝癌患者CIK和正常人CIK一样对肝癌细胞有很强的细胞毒作用 ,对耐药肿瘤同样有效 ,对正常肝细胞无损伤 ,具有临床应用前景
To observe the ability of PBMC induced into CIK cells in vitro and its cytotoxic effect on hepatoma cells. Differences in amplification between CIK cells and LAK cells were compared between normal and hepatocellular carcinoma patients. Cytotoxicity of CIK cells and LAK cells to various cell lines of hepatocellular carcinoma cell line SMMC 772 1 and other cell lines were detected by flow cytometry, CD3, CD5 6 and 3 H TdR release assay. The results showed that the multiplication of CIK cells in hepatocellular carcinoma group and normal group were respectively 6.43 times and 6.74 times, and the multiplication of CD3 + CD5 + cells reached more than 600 times. In the cell proliferation curve and cells There was no difference in surface markers between LAK cells and LAK cells. The cytotoxicity of CIK against hepatocellular carcinoma cells SMMC 772 1, Bel 74 0 2 and Hep 3b reached 65% ~ 81% The cytotoxicity of LK-2 on normal fetal hepatocyte cell line L 0 2 was less than 5%; the cytotoxic effect of CIK on both resistant and non-induced K562 cell in HCC patients reached 70 %about. CIK in liver cancer patients have the same strong cytotoxic effect on liver cancer cells as normal CIK, and are equally effective on drug resistant tumors and have no damage to normal liver cells, and have clinical application prospect